DeepSyte™
Bill FeedAll repsScoreboardsPrimariesProAboutSign inGet started
DeepSyte™™

A nonpartisan civic accountability tool. We match federal legislation to your stated values — without partisan bias.

Learn

  • About
  • About the name
  • Methodology
  • Glossary

Legal

  • Privacy
  • Terms of Service
  • Refund Policy
  • Contact

Sources

Bill data from Congress.gov. Summaries from the Congressional Research Service where available.

Follow

  • Bluesky — @deepsyte.app
  • X — @deepsyteapp
All content is for informational purposes only. Always verify against primary sources.
Back to bill feed
118-s-2683Committee
Sign in to get alerts

AMERICAN DRUGS Act

Read the record. Not the rhetoric.

See how your representatives voted on this bill.

DeepSyte matches this bill to the issues you care about and shows whether your reps' votes line up — not party, not press releases. Take the 2-minute values quiz to see your alignment.

Get started freeTake the values quiz

Alignment with your views

Sign in and take the values quiz to see how this bill lines up with what you've said.

Summary

Official CRS summary
Accelerating Movement of Essential Rx Items to Create Access to National Drug Resources for US Government Services Act or the AMERICAN DRUGS Act This bill generally limits coverage of generic drugs under federal health care programs to those that are manufactured domestically. Specifically, the bill prohibits coverage of generic drugs that are manufactured in foreign countries under Medicare, Medicaid, the Children's Health Insurance Program (CHIP), TRICARE, and benefits provided by the Veterans' Administration. Coverage is permitted for foreign-made generic drugs if there are fewer than two other generic versions that are manufactured domestically or if the generic versions that are manufactured domestically are in shortage or soon to be discontinued. The Food and Drug Administration (FDA) must notify appropriate agencies about brand-name drugs that have at least two generic versions that are manufactured domestically and those that do not. The bill also allows the FDA to expedite the development and review of applications for generic versions of brand-name drugs that do not have at least two generic versions that are manufactured domestically.
Read full bill text

Values analysis

Sign in and take the values quiz to get a personalized read on how this bill lines up with your positions.

Bill details

Congress
118
Bill type
s
Introduced
July 27, 2023
Sponsor
Not yet available
Last action
July 27, 2023— Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

How your representatives voted

Sign in to see how your representatives voted on this bill.